92 related articles for article (PubMed ID: 1355467)
1. Antiemetics.
Allan SG
Gastroenterol Clin North Am; 1992 Sep; 21(3):597-611. PubMed ID: 1355467
[TBL] [Abstract][Full Text] [Related]
2. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
[TBL] [Abstract][Full Text] [Related]
3. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
4. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
5. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Egan AP; Taggart JR; Bender CM
Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
7. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
8. [Value of 5-HT3 receptor antagonists, particularly as anti-emetic drugs].
Lechat P
Ann Pharm Fr; 1991; 49(6):307-16. PubMed ID: 1842169
[TBL] [Abstract][Full Text] [Related]
9. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
Goodman M
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
[TBL] [Abstract][Full Text] [Related]
11. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and anti-emetic properties of ondansetron.
Tyers MB; Bunce KT; Humphrey PP
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894
[TBL] [Abstract][Full Text] [Related]
13. [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
d'Allens H; Aubert B; Bons J; Pappo M
Bull Cancer; 1991; 78(12):1139-46. PubMed ID: 1838490
[TBL] [Abstract][Full Text] [Related]
14. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
[TBL] [Abstract][Full Text] [Related]
15. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
16. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Herrstedt J
Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
[TBL] [Abstract][Full Text] [Related]
17. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
18. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
19. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron: a new entity in emesis control.
Graves T
DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
